What are the recommended dose, indications, contraindications, common adverse effects, monitoring parameters, and alternative treatments for plecanatide in adults with chronic idiopathic constipation or irritable bowel syndrome with constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Plecanatide for Chronic Idiopathic Constipation and Irritable Bowel Syndrome with Constipation

Plecanatide 3 mg once daily is strongly recommended for adults with chronic idiopathic constipation (CIC) or irritable bowel syndrome with constipation (IBS-C) who have failed over-the-counter treatments, based on high-quality evidence demonstrating significant improvements in bowel movements, abdominal pain, and quality of life. 1

Indications

Plecanatide is FDA-approved for two specific conditions in adults 2:

  • Chronic idiopathic constipation (CIC)
  • Irritable bowel syndrome with constipation (IBS-C)

The 2023 AGA-ACG guidelines provide a strong recommendation with moderate certainty of evidence for plecanatide use in adults with CIC who do not respond to OTC agents 1. For IBS-C, plecanatide received a conditional recommendation with moderate certainty of evidence 3.

Recommended Dose

The FDA-approved dose is 3 mg taken orally once daily for both CIC and IBS-C 2. This is the only commercially available dose, though 6 mg was studied in clinical trials 1.

Administration Instructions:

  • Take with or without food (unlike linaclotide, which requires fasting) 1, 2
  • Swallow tablets whole when possible
  • If a dose is missed, skip it and resume at the regular time—never double dose 2
  • For patients with swallowing difficulties, tablets can be crushed and mixed with applesauce or water, or administered via nasogastric/gastric feeding tube 2

Mechanism of Action

Plecanatide is a pH-dependent guanylate cyclase-C (GC-C) agonist that increases cyclic guanosine monophosphate concentrations, resulting in luminal chloride and bicarbonate secretion. This increases intestinal fluid and accelerates GI transit 1.

Efficacy Data

For Chronic Idiopathic Constipation:

Based on three 12-week randomized controlled trials 1:

  • Increases complete spontaneous bowel movements (CSBMs) by 1.1 per week (95% CI 0.85–1.35)
  • Increases spontaneous bowel movements (SBMs) by 1.66 per week (95% CI 1.37–1.94)
  • Responder rate: 88 more per 1,000 patients achieved ≥3 CSBMs per week with ≥1 CSBM increase over baseline for ≥9 of 12 weeks (RR 1.78,95% CI 1.46–2.18)
  • Improves quality of life scores with high certainty of evidence
  • Improves stool consistency on Bristol Stool Form Scale (MD 0.83,95% CI 0.6–1.05)

For Irritable Bowel Syndrome with Constipation:

Based on two phase 3 trials 3, 4:

  • FDA composite endpoint (≥30% reduction in abdominal pain AND ≥1 CSBM/week increase for ≥6 of 12 weeks): achieved by 30.2% and 21.5% with plecanatide 3 mg versus 17.8% and 14.2% with placebo (p<0.001 and p=0.009)
  • Reduces abdominal pain with risk difference of 10.1%
  • Improves bloating, particularly in patients with moderate-to-severe baseline bloating 5

Contraindications

Absolute contraindications 2:

  1. Patients less than 6 years of age (BLACK BOX WARNING: risk of serious dehydration and death based on nonclinical studies in young juvenile mice)
  2. Known or suspected mechanical gastrointestinal obstruction

Avoid use in patients 6 years to less than 18 years of age 2

Common Adverse Effects

Most Common:

Diarrhea is the predominant adverse effect 1, 3:

  • Occurs in 4.3% of patients on plecanatide 3 mg versus 1.0% on placebo in IBS-C trials 3
  • Leads to discontinuation in 1.2% of patients (27 more per 1,000 compared to placebo; RR 5.39,95% CI 2.40–12.11) 1
  • The absolute risk of diarrhea-related discontinuation is small despite the relative risk increase 1

Important Safety Notes:

  • Serious adverse events occur at similar rates to placebo (0.8%) 3
  • No diarrhea-related serious adverse events reported in trials 3
  • If severe diarrhea occurs, suspend dosing and rehydrate the patient 2

Monitoring Parameters

While the guidelines do not specify formal monitoring parameters, clinical practice should include:

  • Symptom assessment: Track CSBM frequency, abdominal pain, and bloating severity
  • Adverse effect monitoring: Specifically assess for diarrhea severity
  • Response evaluation: Assess efficacy within 2-4 weeks; trials showed median time to first CSBM was significantly shorter with plecanatide 6
  • Duration: No time limit specified in drug label, though trials evaluated 12 weeks 1, 2

Alternative Treatments

When plecanatide fails or is not tolerated, consider these evidence-based alternatives 1:

Other Prescription Secretagogues:

  1. Linaclotide (72 μg or 145 μg for CIC; 290 μg for IBS-C)

    • Similar efficacy to plecanatide 7
    • Must be taken 30 minutes before first meal on empty stomach 1
    • May be particularly useful for concurrent abdominal discomfort, pain, and bloating 1
    • Diarrhea rates similar to plecanatide based on meta-regression 3

  2. Lubiprostone (24 μg twice daily for CIC; 8 μg twice daily for IBS-C)

    • Chloride channel activator
    • Take with meals to reduce nausea 1
    • Nausea occurs in 35% but leads to discontinuation in only 5% 1

Serotonergic Agents:

  1. Prucalopride (2 mg daily)
    • 5-HT4 agonist
    • Strong recommendation for CIC 1
    • May cause headache, abdominal pain, nausea, and diarrhea 1

Clinical Pearls and Common Pitfalls

Advantages of Plecanatide:

  • Can be taken with or without food (more convenient than linaclotide) 1
  • pH-dependent activity maintains efficacy even with concomitant acid suppression therapy 8
  • Effective in severe constipation: Works in patients with no CSBMs at baseline and severe straining 6
  • Improves multiple symptoms: Addresses both bowel symptoms and abdominal pain/bloating 5

Key Implementation Points:

  • Use as replacement OR adjunct to OTC agents—not necessarily sequential 1
  • No age-related dose adjustments needed: No clear differences in outcomes among patients >65 years, though sample sizes were limited 1
  • Patient counseling is critical: Set expectations about diarrhea risk (4.3%) but emphasize low discontinuation rate (1.2%) 3
  • Consider baseline bloating severity: Patients with moderate-to-severe bloating show particularly robust responses 5

When to Reconsider or Switch:

  • If diarrhea becomes severe, suspend dosing temporarily and rehydrate 2
  • If no response after adequate trial (at least 4-6 weeks), consider switching to alternative class (e.g., prucalopride) rather than another GC-C agonist 9
  • Combination therapy with agents from different classes may be considered for refractory cases 9

Contraindication Vigilance:

Never prescribe to pediatric patients due to BLACK BOX WARNING about dehydration risk 2. Always rule out mechanical obstruction before initiating therapy 2.

References

Related Questions

If Linzess (linaclotide) is not effective, can I try Trulance (plecanatide)?
Should I take Relistor (methylnaltrexone) and Trulance (plecanatide) together?
In a patient with chronic constipation currently taking prucalopride 2 mg twice daily and bixilat 10 mg before dinner, what additional therapy should be prescribed for abdominal fullness and to further improve constipation?
When is the ideal time to prescribe plecanatide and linaclotide (guanylate cyclase-C (GC-C) agonists) for patients with Chronic Idiopathic Constipation (CIC) or Irritable Bowel Syndrome with Constipation (IBS-C)?
In a typical adult patient without contraindications, how soon after taking Trulance (plecanatide) should a bowel movement be expected?
Does losartan increase cancer risk, and should it be discontinued in patients with active malignancy?
What are the ballistic mechanisms and skull regions most vulnerable to penetration by low‑velocity projectiles in head injuries?
Does fecal or serum calprotectin increase during a common cold (viral upper respiratory infection)?
Does multiple myeloma cause macrocytosis?
In a patient with cirrhosis who has elevated gamma‑glutamyl transferase (GGT) and alkaline phosphatase (ALP), what is the appropriate evaluation and management?
How should an isolated elevation of serum T3 with normal free T4 and TSH be evaluated and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.